Novo Nordisk A/S Stock News

The popularity of Novo Nordisk's (NVO) blockbuster obesity drug Wegovy, and diabetes drug Ozempic, for weight loss, was so great in 2023 that it has been credited with propping up the entire economy o

Novo Nordisk is buying Cardior, a clinical-stage biotech that is developing heart disease drugs. Its cardiovascular disease pipeline will get a lot stronger as a result of the acquisition.

Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, includi

Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as El

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

International Companies Drive Diabesity Innovation

The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes could

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market i

As the stock market rally continues, the trillion-dollar market cap club stands to get just a bit more crowded. Undoubtedly, more than a handful of mega-cap titans could pass the $1 trillion milestone

Some large health insurers in the U.S. will start covering Wegovy, which has become a popular anti-obesity drug — but not for those using it to lose weight, according to a report by The Wall Street

Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the “

Researchers found Novo Nordisk's Ozempic could be manufactured for an estimated 89 cents to $4.73 for a month's supply, figures that include a profit margin.

Given the pharmaceutical industry's assured success driven by innovation and the development of medications targeting diverse healthcare issues, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have

The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the domina

As we approach the end of the year's first quarter, the stock market has enjoyed a strong run. Three months into 2024 and the benchmark S&P 500 index is already up 10%.